HLX43

HLX43 is an antibody-drug conjugate developed by Shanghai Henlius Biotech. Its targets are PD-L1 and EGFR (the sponsor names PD-L1). The sponsor states: HLX43 is an anti-PD-L1 antibody-drug conjugate (ADC), studied as monotherapy or combined with the anti-EGFR antibody HLX07. ClinicalTrials.gov describes the intervention as: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07459751 (A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer), in non-small-cell lung cancer, cervical cancer, ovarian cancer and oesophageal cancer. The largest, NCT07459751, plans to enrol 706 participants with primary completion expected 2030-01-15. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.